Prompt Response from Septa to Address Tier 3 Shortage is Key to Minimizing Impact on Patients
Mississauga, ON — May 31, 2024 — Septa Pharma Inc., a renowned provider of critical medications in Canada, has received approval from Health Canada to import Carbamazepine Extended Release Tablets, available in 200 mg and 400 mg doses. This measure addresses the pressing shortage of this essential medication used primarily for managing epilepsy and neuropathic pain.
Septa’s swift action highlights its dedication to ensuring continuous access to high-quality medications. Leveraging a robust global network, Septa bridges the gap between demand and supply, ensuring Canadian healthcare providers have the necessary resources to deliver optimal patient care.
“Our goal is to mitigate the impact of drug shortages on Canadian communities,” states the CEO. “The approval to import Carbamazepine Extended Release Tablets underscores our commitment to patient well-being and healthcare system support during critical times.”
Through these efforts, Septa reaffirms its role as a reliable partner in healthcare, dedicated to quality, reliability, and timely solutions.
About Septa: Septa Pharma Inc. is a global healthcare conglomerate providing essential pharmaceuticals and healthcare products to enhance quality of life worldwide. For further information, visit SeptaLife.com.
For media inquires, please contact:
Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665
